Obstet Gynecol Sci.  2020 Mar;63(2):150-157. 10.5468/ogs.2020.63.2.150.

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study

Affiliations
  • 1Department of Medicine, College of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
  • 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. joelcardenas@ufl.edu
  • 3Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
  • 4Department of Radiology, College of Medicine, University of Florida, Gainesville, FL, USA.

Abstract


OBJECTIVE
The primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine the perioperative outcomes.
METHODS
A retrospective study of 12 patients with stage IIIC or IV ovarian, fallopian tube, and primary peritoneal carcinoma who underwent interval cytoreductive surgery after neo-adjuvant chemotherapy.
RESULTS
Optimal cytoreduction was achieved in 100% of selected patients. Complete cytoreductive surgery was achieved in 75% of patients. The estimated mean blood loss was 100 mL. The median length of hospital stay was 2 days. Perioperative complication and 30-day readmission rates were 8.3% (1 patient). The median follow-up time was 9.5 months.
CONCLUSION
Robotic-assisted interval cytoreductive surgery in ovarian cancer is safe and feasible and may be an alternative to standard laparotomy in selected patients.

Keyword

Robotic surgical procedure; Ovarian cancer; Cytoreductive surgical procedure

MeSH Terms

Cytoreduction Surgical Procedures
Drug Therapy
Fallopian Tubes
Feasibility Studies*
Female
Follow-Up Studies
Humans
Laparotomy
Length of Stay
Ovarian Neoplasms*
Retrospective Studies
Robotic Surgical Procedures

Cited by  2 articles

Safety and feasibility of robotic surgery in selected ovarian cancer patients undergoing interval debulking surgery
Christos Iavazzo, Ioannis D. Gkegkes
Obstet Gynecol Sci. 2020;63(5):553-554.    doi: 10.5468/ogs.20085.

Comparison of single-port laparoscopy and laparotomy in early ovarian cancer surgical staging
Kyu Hee Cho, Yeon Ju Lee, Kyung Jin Eoh, Yong Jae Lee, Jung-Yun Lee, Eun Ji Nam, Sunghoon Kim, Young Tae Kim, Sang Wun Kim
Obstet Gynecol Sci. 2021;64(1):90-98.    doi: 10.5468/ogs.20216.


Reference

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7–34. PMID: 30620402.
Article
2. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363:943–953. PMID: 20818904.
Article
3. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386:249–257. PMID: 26002111.
Article
4. Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer. 2016; 64:22–31. PMID: 27323348.
Article
5. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MK, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018; 19:1680–1687. PMID: 30413383.
Article
6. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016; 34:3460–3473. PMID: 27502591.
Article
7. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012; 125:483–492. PMID: 22366151.
Article
8. Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, et al. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018; 148:275–280. PMID: 29195926.
Article
9. Schorge JO, Bregar AJ, Durfee J, Berkowitz RS. Meigs to modern times: the evolution of debulking surgery in advanced ovarian cancer. Gynecol Oncol. 2018; 149:447–454. PMID: 29525276.
Article
10. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016; 59:22–33. PMID: 26998845.
Article
11. Melamed A, Nitecki R, Boruta DM 2nd, Del Carmen MG, Clark RM, Growdon WB, et al. Laparoscopy compared with laparotomy for debulking ovarian cancer after neoadjuvant chemotherapy. Obstet Gynecol. 2017; 129:861–869. PMID: 28383367.
Article
12. Gueli Alletti S, Bottoni C, Fanfani F, Gallotta V, Chiantera V, Costantini B, et al. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Am J Obstet Gynecol. 2016; 214:503.e1–503.e6. PMID: 26529370.
Article
13. National Comprehensive Cancer Network. National Comprehensive Cancer Network's practice guidelines in oncology. Ovarian cancer [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network;c2018. cited 2019 May 1. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
14. Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien PA, Reeves BC, et al. Challenges in evaluating surgical innovation. Lancet. 2009; 374:1097–1104. PMID: 19782875.
Article
15. Garas G, Cingolani I, Panzarasa P, Darzi A, Athanasiou T. Network analysis of surgical innovation: measuring value and the virality of diffusion in robotic surgery. PLoS One. 2017; 12:e0183332. PMID: 28841648.
Article
16. Rutten MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, Naaktgeboren CA, van Gorp T, et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol. 2017; 35:613–621. PMID: 28029317.
Article
17. Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015; 33:2457–2463. PMID: 26124480.
Article
18. Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, et al. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations--part I. Gynecol Oncol. 2016; 140:313–322. PMID: 26603969.
19. Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, et al. Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations--part II. Gynecol Oncol. 2016; 140:323–332. PMID: 26757238.
20. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007; 107:99–106. PMID: 17602726.
Article
21. Lucidi A, Chiantera V, Gallotta V, Ercoli A, Scambia G, Fagotti A. Role of robotic surgery in ovarian malignancy. Best Pract Res Clin Obstet Gynaecol. 2017; 45:74–82. PMID: 28602522.
Article
22. Magrina JF, Zanagnolo V, Noble BN, Kho RM, Magtibay P. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol. 2011; 121:100–105. PMID: 21194736.
Article
23. Nezhat FR, Finger TN, Vetere P, Radjabi AR, Vega M, Averbuch L, et al. Comparison of perioperative outcomes and complication rates between conventional versus robotic-assisted laparoscopy in the evaluation and management of early, advanced, and recurrent stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2014; 24:600–607. PMID: 24557439.
Article
24. Feuer GA, Lakhi N, Barker J, Salmieri S, Burrell M. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol. 2013; 131:520–524. PMID: 24080421.
Article
25. Ackroyd SA, Thomas S, Angel C, Moore R, Meacham PJ, DuBeshter B. Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer. J Robot Surg. 2018; 12:245–250. PMID: 28631233.
Article
26. Tozzi R, Gubbala K, Majd HS, Campanile RG. Interval laparoscopic en-bloc resection of the pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: description of the technique and surgical outcomes. Gynecol Oncol. 2016; 142:477–483. PMID: 27450637.
Article
27. Favero G, Macerox N, Pfiffer T, Köhler C, da Costa Miranda V, Estevez Diz MP, et al. Oncologic concerns regarding laparoscopic cytoreductive surgery in patients with advanced ovarian cancer submitted to neoadjuvant chemotherapy. Oncology. 2015; 89:159–166. PMID: 25968072.
Article
28. Corrado G, Mancini E, Cutillo G, Baiocco E, Vici P, Sergi D, et al. Laparoscopic debulking surgery in the management of advanced ovarian cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer. 2015; 25:1253–1257. PMID: 26111273.
Article
29. Cardenas-Goicoechea J, Wang Y, McGorray S, Saleem MD, Carbajal Mamani SL, Pomputius AF, et al. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis. J Robot Surg. 2019; 13:23–33. PMID: 29992404.
Article
30. Brown J, Drury L, Crane EK, Anderson WE, Tait DL, Higgins RV, et al. When less is more: minimally invasive surgery compared with laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer. J Minim Invasive Gynecol. 2019; 26:902–909. PMID: 30240899.
Article
31. Fagotti A, Gueli Alletti S, Corrado G, Cola E, Vizza E, Vieira M, et al. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy. Int J Gynecol Cancer. 2019; 29:5–9. PMID: 30640676.
Article
Full Text Links
  • OGS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr